Benzodiazepines interfere with the efficacy of pembrolizumab-based cancer immunotherapy. Results of a nationwide cohort study including over 50,000 participants with advanced lung cancer
Open accessThe DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Abstract
We previously reported that elevated levels of diazepam binding inhibitor (DBI), also called ‘endozepine’ because it acts as an endogenous benzodiazepine equivalent on the gamma-aminobutyric acid type A receptor, constitutes a potential risk factor for the diagnosis of non-small cell lung cancer (NSCLC). Antibody-mediated neutralization of DBI improved the immunosurveillance of NSCLC in preclinical models with and without immunotherapy targeting programmed cell death protein 1 (PD-1). A pilot study in a small French-Canadian cohort (n = 205) suggested that benzodiazepine (BZD) use correlates with reduced progression-free survival in NSCLC patients receiving PD-1/PD-L1 blockade. Here, we report a retrospective analysis of the nation-wide French registry of advanced NSCLC patients treated with pembrolizumab. Among the eligible NSCLC patients surviving ≥2 months after treatment initiation (n = 31,479), 37.7% (n = 11,878) received at least two prescriptions of benzodiazepines within 90 days before to 30 days after treatment initiation. Compared to non-users (n = 19,601), BZD users had significantly reduced overall survival (hazard ratio = 1.08, 95% CI: 1.04–1.12, p < 0.001), an effect that persisted after correction using inverse probability of treatment weighting (IPTW) on sociodemographic, clinical, oncologic, and comedication variables. In a subset of 556 patients from the ONCOBIOTICS study, benzodiazepine use was associated with signs of intestinal dysbiosis and alterations in the TOPOSCORE, a prognostic marker linked to poorer outcomes in cancer patients receiving immunotherapy. We conclude that benzodiazepine use may be an independent negative prognostic factor for NSCLC patients under pembrolizumab-based immunotherapy. Future studies must determine whether withdrawal of benzodiazepines or neutralization of DBI improves the clinical response to immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Benzodiazepine has also been shown to compromise immunotherapy, with preclinical and clinical data demonstrating that these agents suppress anti-tumor immune responses and correlate with reduced survival in NSCLC patients receiving programmed death protein-1 (PD-1) blockade.90,106”
From Gut dysbiosis in oncology: a risk factor for immunoresistance (2026) · doi:10.1038/s41422-025-01212-6 · cites this paper as [90]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Giaquinto, A. N., & Jemal, A. (2024) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21820 · Cited by 9,533 · cited 1×
“7 In France, patients with advanced, inoperable NSCLC expressing high PD-L1 levels (on ≥50% of the malignant cells) receive the anti-PD1 monoclonal antibody (mAb) pembrolizumab, while patients expressing lower PD-L1 levels ( 50”
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Self-citationThe Human Intestinal Microbiome in Health and Disease
Lynch, S. V., & Pedersen, O. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1600266 · Cited by 3,637 · cited 1×
“In an effort to define clinically relevant signatures, 13 we demonstrated that an increase in harmful fecal bacteria from the unfavorable species-interacting group (SIG) SIG1, a decrease in beneficial bacteria from the favorable group SIG2, or any deviation from the optimal relative abundance of…”
Immune checkpoint therapy—current perspectives and future directions
Sharma, P., Goswami, S., Raychaudhuri, D., Siddiqui, B. A., Singh, P., Nagarajan, A., Liu, J., Subudhi, S. K., Poon, C., Gant, K. L., et al. (2023) · Cell · doi:10.1016/j.cell.2023.03.006 · Cited by 1,206
Tuppin, P., Rudant, J., Constantinou, P., Gastaldi-Ménager, C., Rachas, A., de Roquefeuil, L., Maura, G., Caillol, H., Tajahmady, A., Coste, J., et al. (2017) · Revue d'Épidémiologie et de Santé Publique · doi:10.1016/j.respe.2017.05.004 · Cited by 891
Impact of commonly used drugs on the composition and metabolic function of the gut microbiota
Vich Vila, A., Collij, V., Sanna, S., Sinha, T., Imhann, F., Bourgonje, A. R., Mujagic, Z., Jonkers, D. M. A. E., Masclee, A. A. M., Fu, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-14177-z · Cited by 791 · cited 1×
“…between these two phenomena is still ambiguous since, on the one hand, oral benzodiazepine administration may affect the intestinal microbiota, 46,47 and on the other hand, gut intestinal dysbiosis may affect immunity, general and mental health, hence increasing the need for benzodiazepine…”
Derosa, L., Routy, B., Thomas, A. M., Iebba, V., Zalcman, G., Friard, S., Mazieres, J., Audigier-Valette, C., Moro-Sibilot, D., Goldwasser, F., et al. (2022) · Nature Medicine · doi:10.1038/s41591-021-01655-5 · Cited by 685 · cited 1×
“…from the optimal relative abundance of Akkermansia species, as epitomized in the TOPOSCORE, could predict the success of immunotherapy in NSCLC. 14,15 Recently, we also identified the elevation of the circulating levels of diazepam binding inhibitor (DBI, also known as acyl CoA binding protein,…”
Self-citationGuidotti, A., Forchetti, C. M., Corda, M. G., Konkel, D., Bennett, C. D., & Costa, E. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.11.3531 · Cited by 644
Embracing cancer complexity: Hallmarks of systemic disease
Swanton, C., Bernard, E., Abbosh, C., André, F., Auwerx, J., Balmain, A., Bar-Sagi, D., Bernards, R., Bullman, S., DeGregori, J., et al. (2024) · Cell · doi:10.1016/j.cell.2024.02.009 · Cited by 540 · cited 1×
“3 Accordingly, treatments designed to enhance the anticancer immune response are now occupying a central stage in the clinical management of multiple cancer types including non-small cell lung cancer (NSCLC), 4–6 which is one of the most frequent malignancies affecting both men and women.”
Cited by
Gut dysbiosis in oncology: a risk factor for immunoresistance
(2026) · doi:10.1038/s41422-025-01212-6 · Cited by 24
Self-citationPan, H., Shen, Z., Zhao, L., Liu, P., Jin, Z., Piard, E., Xue, E., Lambertucci, F., Stoll, G., Carbonnier, V., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2518983123 · Cited by 6
“…pharmacological analogues of ACBP/DBI binding to the same receptor (GABA A receptor with α 1 and γ 2 subunits) (25), exert immunosuppressive effects (26) that reduce the efficacy of PD - 1 blockade in NSCLC patients (27–29) and that increase the risk of developing severe infectious disease (26).”
Self-citationAssociations Between Anxiety or Depression Diagnosis and Immune Checkpoint Inhibitor Outcomes
Derry, H. M., Shah, N. J., Ahn, J., DeAgresta, B., Pia, A. D., Zaemes, J. P., Pascual, L., Arias‐Orozco, N., Zemel, R., Sidarous, G. K., et al. (2025) · Cancer Medicine · doi:10.1002/cam4.71326 · Cited by 5
Fidelle, M., Chen, H., Montégut, L., Boulate, D., Abdayem, P., Martineau, M., Kuznetsova, T., van der Aalst, C. M., de Koning, H. J., Zitvogel, L., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02507-3 · Cited by 4
“…it appears intriguing - at least at the speculative level - that long-term treatments with benzodiazepines, which act on the same GABA receptor as ACBP/DBI, increase the risk of lung cancer development and reduces the efficacy of PD-1 blockade against non-small cell lung cancer in patients [13].”
Self-citationLambertucci, F., Motiño, O., Nogueira-Recalde, U., Rong, Y., Montégut, L., Pérez-Lanzón, M., Carbonnier, V., Li, S., Durand, S., Aprahamian, F., et al. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02670-z · Cited by 6
Self-citation
Metadata
- Authors
- Montégut, L., Rousseau, A., Ungolo, C., Derosa, L., Fidelle, M., Alves Costa Silva, C., Routy, B., Zitvogel, L., Besse, B., Pasolli, E., & Kroemer, G.
- Affiliations
- Inserm (FR)
- Université Paris-Saclay (FR)
- Université Paris-Saclay
- Centre Hospitalier de l’Université de Montréal (CA)
- University of Naples Federico II (IT)
- Corresponding author
- Pasolli, Edoardo
- Kroemer, Guido
- ORCID
- Venue
- OncoImmunology
- Publisher
- Informa UK Limited
- Published
- 2025-07-04
- Volume
- 14
- Issue
- 1
- Pages
- 2528955-2528955
- ISSN
- 2162-4011 (ISSN-L)
- 2162-402X
- PMC
- PMC12233713
- OpenAlex
- W4412034547
- Cited by
- 8
- References
- 67
- Citations by year
- 2026: 6 · 2025: 2
- FWCI
- 3.31
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- OncoImmunology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- HAL (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Gustave Roussy Foundation
- European Union’s Horizon 2020 research and innovation program
- French Ministry of Health PIA5
- SIGN’IT ARC Foundation (MICROBIONT-PREDICT (2021))
- European Research Council (ERC-2023-ADG - MADCAM – 101142062, ERC-2021-ADG)
- IHMCSA (964590)
- Institut National du Cancer (INCA_ 16698)
- Ligue contre le Cancer
- Agence National de la Recherche (ANR-22-CE14-0066)
- Association pour la recherche sur le cancer
- Cancéropôle Ile-de-France
- Fondation pour la Recherche Médicale
- Elior
- European Joint Program on Rare Diseases
- European Union Horizon 2020 research and innovation programmes
- Agence Nationale de la Recherche (21-ESRE-0028)
- Hevolution Network on Senescence in Aging (HF-E Einstein Network)
- Institut Universitaire de France
- LabEx Immuno-Oncology
- Seerave Foundation
- SIRIC Cancer Research and Personalized Medicine (CARPEM INCa-DGOS-Inserm-ITMO Cancer_18006)
- IdEx Université de Paris Cité
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- benzodiazepines, pembrolizumab, non-small cell lung cancer, cancer immunotherapy, diazepam binding inhibitor, endozepines, PD-1/PD-L1 blockade, overall survival, prognostic factors, gut dysbiosis, GABAA receptor, drug-drug interactions
- MeSH terms
- Antineoplastic Agents, Immunological, Immune Checkpoint Inhibitors, Adult, Aged, Aged, 80 and over, Benzodiazepines, Carcinoma, Non-Small-Cell Lung, Female, France, Humans, Immunotherapy, Lung Neoplasms, Male, Middle Aged, Retrospective Studies, Treatment Outcome, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Benzodiazepines interfere with the efficacy of pembrolizumab-based cancer immunotherapy. Results of a nationwide cohort study including over 50,000 participants with advanced lung cancer. https://app.cochat.ai/papers/10.1080/2162402x.2025.2528955
- The paper
- Montégut, L., Rousseau, A., Ungolo, C., Derosa, L., Fidelle, M., Alves Costa Silva, C., Routy, B., Zitvogel, L., Besse, B., Pasolli, E., & Kroemer, G. (2025). Benzodiazepines interfere with the efficacy of pembrolizumab-based cancer immunotherapy. Results of a nationwide cohort study including over 50,000 participants with advanced lung cancer. OncoImmunology. https://doi.org/10.1080/2162402x.2025.2528955
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.